Answers are grounded in this paper and cite their sources.
Observational analysis revealed cognitive decline is associated with higher phosphorylated tau in early AD, suggesting treatment implications for lecanemab.
Lecanemab was generally well tolerated by most patients with early AD and treatment appeared to be more effective and safer in patients with low CSF-ptau181 levels. Our results suggest an association between lecanemab treatment and reduced markers of vascular endothelial injury.
No takes yet. Share an insight, caveat, or question.
Noguchi‐Shinohara et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: